American Association for Cancer Research (AACR)

Clinical Cancer Research

, volume 29 , issue 16 , pages OF1-OF16

Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

Vivek Subbiah ¹

Sant P Chawla ²

Anthony Conley ³

Breelyn A. Wilky ⁴

Anthony W. Tolcher ⁵

Nehal J. Lakhani ⁶

David Berz ⁷

Vasily Andrianov ⁸

William Crago ⁸

Monica Holcomb ⁸

Abrahim Hussain ⁸

Carson Veldstra ⁸

James Kalabus ⁸

Brianne O’Neill ⁸

Lane Senne ⁸

Emily Rowell ⁸

Analeah B. Heidt ⁸

Katelyn M. Willis ⁸

Brendan P. Eckelman ⁸

Hide authors affiliations Show authors affiliations: 8 affiliations

1Department of Investigational Cancer Therapeutics, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas; Sarah Cannon Research Institute, Nashville, Tennessee. |

2Sarcoma Oncology Research Center, Santa Monica, California. |

3Department of Sarcoma Medical Oncology, Division of Cancer Medicine, The University of Texas MD Anderson Cancer Center, Houston, Texas. |

⁴

4Department of Medicine, Division of Medical Oncology, University of Colorado School of Medicine, Aurora, Colorado. |

⁵

5NEXT Oncology, San Antonio, Texas. |

⁶

6START Midwest, Michigan. |

⁷

7Valkyrie Clinical Trials, Los Angeles, California. |

⁸

8Inhibrx, Inc, La Jolla, California. |

Publication type: Journal Article

Publication date: 2023-06-02

American Association for Cancer Research (AACR)

Clinical Cancer Research

scimago Q1

wos Q1

SJR: 4.800

CiteScore: 19.0

Impact factor: 10.2

ISSN: 10780432, 15573265

DOI: 10.1158/1078-0432.ccr-23-0974

Copy DOI

PubMed ID: 37265425

Cancer Research

Oncology

Abstract

Purpose:

Patients with unresectable/metastatic chondrosarcoma have poor prognoses; conventional chondrosarcoma is associated with a median progression-free survival (PFS) of <4 months after first-line chemotherapy. No standard targeted therapies are available. We present the preclinical characterization of INBRX-109, a third-generation death receptor 5 (DR5) agonist, and clinical findings from a phase I trial of INBRX-109 in unresectable/metastatic chondrosarcoma (NCT03715933).

Patients and Methods:

INBRX-109 was first characterized preclinically as a DR5 agonist, with binding specificity and hepatotoxicity evaluated in vitro and antitumor activity evaluated both in vitro and in vivo. INBRX-109 (3 mg/kg every 3 weeks) was then evaluated in a phase I study of solid tumors, which included a cohort with any subtype of chondrosarcoma and a cohort with IDH1/IDH2-mutant conventional chondrosarcoma. The primary endpoint was safety. Efficacy was an exploratory endpoint, with measures including objective response, disease control rate, and PFS.

Results:

In preclinical studies, INBRX-109 led to antitumor activity in vitro and in patient-derived xenograft models, with minimal hepatotoxicity. In the phase I study, INBRX-109 was well tolerated and demonstrated antitumor activity in unresectable/metastatic chondrosarcoma. INBRX-109 led to a disease control rate of 87.1% [27/31; durable clinical benefit, 40.7% (11/27)], including two partial responses, and median PFS of 7.6 months. Most treatment-related adverse events, including liver-related events, were low grade (grade ≥3 events in chondrosarcoma cohorts, 5.7%).

Conclusions:

INBRX-109 demonstrated encouraging antitumor activity with a favorable safety profile in patients with unresectable/metastatic chondrosarcoma. A randomized, placebo-controlled, phase II trial (ChonDRAgon, NCT04950075) will further evaluate INBRX-109 in conventional chondrosarcoma.

Found

1 citation

Yagolovich Anne

🥼 🤝

PhD in Biological/biomedical sciences, lecturer

31 publications, 267 citations, 4 reviews

h-index: 10

Lomonosov Moscow State University

Shemyakin-Ovchinnikov Institute of Bioorganic Chemistry of the Russian Academy of Sciences

Research interests

Apoptosis

Top-30

Journals

	1 2
mAbs	mAbs, 2, 6.25% mAbs 2 publications, 6.25%
medRxiv : the preprint server for health sciences	medRxiv : the preprint server for health sciences, 1, 3.13% medRxiv : the preprint server for health sciences 1 publication, 3.13%
Journal of Drug Delivery Science and Technology	Journal of Drug Delivery Science and Technology, 1, 3.13% Journal of Drug Delivery Science and Technology 1 publication, 3.13%
Current Opinion in Oncology	Current Opinion in Oncology, 1, 3.13% Current Opinion in Oncology 1 publication, 3.13%
American Society of Clinical Oncology Educational Book	American Society of Clinical Oncology Educational Book, 1, 3.13% American Society of Clinical Oncology Educational Book 1 publication, 3.13%
EBioMedicine	EBioMedicine, 1, 3.13% EBioMedicine 1 publication, 3.13%
Journal of Clinical Investigation	Journal of Clinical Investigation, 1, 3.13% Journal of Clinical Investigation 1 publication, 3.13%
Biomedicines	Biomedicines, 1, 3.13% Biomedicines 1 publication, 3.13%
Frontiers in Molecular Biosciences	Frontiers in Molecular Biosciences, 1, 3.13% Frontiers in Molecular Biosciences 1 publication, 3.13%
MedComm	MedComm, 1, 3.13% MedComm 1 publication, 3.13%
Nature Reviews Drug Discovery	Nature Reviews Drug Discovery, 1, 3.13% Nature Reviews Drug Discovery 1 publication, 3.13%
Targeted Oncology	Targeted Oncology, 1, 3.13% Targeted Oncology 1 publication, 3.13%
Antibody Therapeutics	Antibody Therapeutics, 1, 3.13% Antibody Therapeutics 1 publication, 3.13%
Journal of Translational Medicine	Journal of Translational Medicine, 1, 3.13% Journal of Translational Medicine 1 publication, 3.13%
Oncology and Therapy	Oncology and Therapy, 1, 3.13% Oncology and Therapy 1 publication, 3.13%
Cancer	Cancer, 1, 3.13% Cancer 1 publication, 3.13%
Expert Opinion on Emerging Drugs	Expert Opinion on Emerging Drugs, 1, 3.13% Expert Opinion on Emerging Drugs 1 publication, 3.13%
Russian Chemical Reviews	Russian Chemical Reviews, 1, 3.13% Russian Chemical Reviews 1 publication, 3.13%
International Journal of Molecular Sciences	International Journal of Molecular Sciences, 1, 3.13% International Journal of Molecular Sciences 1 publication, 3.13%
Current Treatment Options in Oncology	Current Treatment Options in Oncology, 1, 3.13% Current Treatment Options in Oncology 1 publication, 3.13%
Frontiers in Pharmacology	Frontiers in Pharmacology, 1, 3.13% Frontiers in Pharmacology 1 publication, 3.13%
Scientific Reports	Scientific Reports, 1, 3.13% Scientific Reports 1 publication, 3.13%
Bulletin du Cancer	Bulletin du Cancer, 1, 3.13% Bulletin du Cancer 1 publication, 3.13%
Current Oncology Reports	Current Oncology Reports, 1, 3.13% Current Oncology Reports 1 publication, 3.13%
BioDrugs	BioDrugs, 1, 3.13% BioDrugs 1 publication, 3.13%
Expert Opinion on Drug Metabolism and Toxicology	Expert Opinion on Drug Metabolism and Toxicology, 1, 3.13% Expert Opinion on Drug Metabolism and Toxicology 1 publication, 3.13%
Clinical Cancer Research	Clinical Cancer Research, 1, 3.13% Clinical Cancer Research 1 publication, 3.13%
International Journal of Cancer	International Journal of Cancer, 1, 3.13% International Journal of Cancer 1 publication, 3.13%
Biomaterials Advances	Biomaterials Advances, 1, 3.13% Biomaterials Advances 1 publication, 3.13%
European Journal of Pharmacology	European Journal of Pharmacology, 1, 3.13% European Journal of Pharmacology 1 publication, 3.13%
	1 2

Publishers

	1 2 3 4 5 6 7 8
Springer Nature	Springer Nature, 8, 25% Springer Nature 8 publications, 25%
Elsevier	Elsevier, 5, 15.63% Elsevier 5 publications, 15.63%
Taylor & Francis	Taylor & Francis, 4, 12.5% Taylor & Francis 4 publications, 12.5%
MDPI	MDPI, 3, 9.38% MDPI 3 publications, 9.38%
Wiley	Wiley, 3, 9.38% Wiley 3 publications, 9.38%
Frontiers Media S.A.	Frontiers Media S.A., 2, 6.25% Frontiers Media S.A. 2 publications, 6.25%
Ovid Technologies (Wolters Kluwer Health)	Ovid Technologies (Wolters Kluwer Health), 1, 3.13% Ovid Technologies (Wolters Kluwer Health) 1 publication, 3.13%
American Society of Clinical Oncology (ASCO)	American Society of Clinical Oncology (ASCO), 1, 3.13% American Society of Clinical Oncology (ASCO) 1 publication, 3.13%
American Society for Clinical Investigation	American Society for Clinical Investigation, 1, 3.13% American Society for Clinical Investigation 1 publication, 3.13%
Oxford University Press	Oxford University Press, 1, 3.13% Oxford University Press 1 publication, 3.13%
Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii	Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii, 1, 3.13% Autonomous Non-profit Organization Editorial Board of the journal Uspekhi Khimii 1 publication, 3.13%
American Association for Cancer Research (AACR)	American Association for Cancer Research (AACR), 1, 3.13% American Association for Cancer Research (AACR) 1 publication, 3.13%
	1 2 3 4 5 6 7 8

We do not take into account publications without a DOI.
Statistics recalculated weekly.

Are you a researcher?

Create a profile to get free access to personal recommendations for colleagues and new articles.

Metrics

Cite this

GOST |

Cite this

GOST Copy

Subbiah V. et al. Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma // Clinical Cancer Research. 2023. Vol. 29. No. 16. p. OF1-OF16.

GOST all authors (up to 50) Copy

Subbiah V., Chawla S. P., Conley A., Wilky B. A., Tolcher A. W., Lakhani N. J., Berz D., Andrianov V., Crago W., Holcomb M., Hussain A., Veldstra C., Kalabus J., O’Neill B., Senne L., Rowell E., Heidt A. B., Willis K. M., Eckelman B. P. Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma // Clinical Cancer Research. 2023. Vol. 29. No. 16. p. OF1-OF16.

RIS |

Cite this

RIS Copy

TY - JOUR

DO - 10.1158/1078-0432.ccr-23-0974

UR - https://doi.org/10.1158/1078-0432.ccr-23-0974

TI - Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma

T2 - Clinical Cancer Research

AU - Subbiah, Vivek

AU - Chawla, Sant P

AU - Conley, Anthony

AU - Wilky, Breelyn A.

AU - Tolcher, Anthony W.

AU - Lakhani, Nehal J.

AU - Berz, David

AU - Andrianov, Vasily

AU - Crago, William

AU - Holcomb, Monica

AU - Hussain, Abrahim

AU - Veldstra, Carson

AU - Kalabus, James

AU - O’Neill, Brianne

AU - Senne, Lane

AU - Rowell, Emily

AU - Heidt, Analeah B.

AU - Willis, Katelyn M.

AU - Eckelman, Brendan P.

PY - 2023

DA - 2023/06/02

PB - American Association for Cancer Research (AACR)

SP - OF1-OF16

IS - 16

VL - 29

PMID - 37265425

SN - 1078-0432

SN - 1557-3265

ER -

BibTex |

Cite this

BibTex (up to 50 authors) Copy

@article{2023_Subbiah,

author = {Vivek Subbiah and Sant P Chawla and Anthony Conley and Breelyn A. Wilky and Anthony W. Tolcher and Nehal J. Lakhani and David Berz and Vasily Andrianov and William Crago and Monica Holcomb and Abrahim Hussain and Carson Veldstra and James Kalabus and Brianne O’Neill and Lane Senne and Emily Rowell and Analeah B. Heidt and Katelyn M. Willis and Brendan P. Eckelman},

title = {Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma},

journal = {Clinical Cancer Research},

year = {2023},

volume = {29},

publisher = {American Association for Cancer Research (AACR)},

month = {jun},

url = {https://doi.org/10.1158/1078-0432.ccr-23-0974},

number = {16},

pages = {OF1--OF16},

doi = {10.1158/1078-0432.ccr-23-0974}

}

MLA

Cite this

MLA Copy

Subbiah, Vivek, et al. “Preclinical Characterization and Phase 1 Trial Results of INBRX-109, a Third-Generation, Recombinant, Humanized, Death Receptor 5 Agonist Antibody, in Chondrosarcoma.” Clinical Cancer Research, vol. 29, no. 16, Jun. 2023, pp. OF1-OF16. https://doi.org/10.1158/1078-0432.ccr-23-0974.

Publisher

American Association for Cancer Research (AACR)

Journal

Clinical Cancer Research

scimago Q1

wos Q1

SJR

4.800

CiteScore

19.0

Impact factor

10.2

ISSN

10780432 (Print)

15573265 (Electronic)

Profiles

Breelyn A Wilky